Pro-Pharmaceuticals, Inc. Announces Significant Advance in Defining DAVANAT(R)'s Mechanism of Action Based on Experiments Done at the University of Minnesotaand the Ludwig Institute For Cancer Research (LICR) in Brussels, Belgium
Published: Dec 17, 2009
NEWTON, Mass.--(BUSINESS WIRE)--Pro-Pharmaceuticals, Inc. (OTC: PRWP), a developer of Galectin-targeting, carbohydrate therapeutic compounds to treat cancer and fibrosis, today announced it has made significant advances in determining the mechanism of action for its lead drug DAVANAT®. Recent studies conducted by Dr. Kevin Mayo at the University of Minnesota demonstrate DAVANAT® binds to Galectin-1, a receptor that controls angiogenesis of cancer tumors. Angiogenesis, the ability to form new blood vessels, represents a critical step in tumor development through which the tumor establishes an independent blood supply, consequently facilitating tumor growth.